Olr180 inhibitors represent a chemical class of compounds that specifically target and modulate the activity of the Olr180 receptor. Olr180, part of the olfactory receptor (OR) family, is a G-protein-coupled receptor (GPCR) primarily involved in the detection of odor molecules. These receptors play a pivotal role in the olfactory system by transducing chemical signals from odorants into neuronal responses, enabling the sense of smell. The inhibition of Olr180 receptors is achieved through compounds that interact with the receptor's active site or allosteric sites, effectively preventing the receptor from binding to its natural ligands or altering its conformational state. This modulation of Olr180 can be highly specific, depending on the structure of the inhibitor, which typically mimics or competes with natural odorants or employs unique chemical scaffolds that interfere with receptor activity.
The structural chemistry of Olr180 inhibitors is of particular interest in the field of molecular biology and receptor pharmacology. These inhibitors are often characterized by their ability to maintain high specificity and affinity for the Olr180 receptor, a feature that is crucial in studying the receptor's function in a controlled manner. The chemical architecture of these inhibitors may include aromatic rings, heterocyclic cores, and various functional groups that enhance receptor binding through hydrogen bonding, hydrophobic interactions, and Van der Waals forces. Additionally, the development of Olr180 inhibitors involves rigorous screening and synthesis processes, where structure-activity relationship (SAR) studies are crucial to optimizing their efficacy. This class of compounds serves as valuable tools in the exploration of olfactory receptor signaling pathways, aiding in the broader understanding of GPCR function and the molecular mechanisms underlying olfaction.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor, may impact protein degradation processes involving Olr180. | ||||||
Dabrafenib | 1195765-45-7 | sc-364477 sc-364477A sc-364477B sc-364477C sc-364477D | 5 mg 25 mg 50 mg 100 mg 10 g | $141.00 $260.00 $278.00 $411.00 $12485.00 | 6 | |
BRAF inhibitor, potentially affects pathways linked to Olr180's activity. | ||||||
MDV3100 | 915087-33-1 | sc-364354 sc-364354A | 5 mg 50 mg | $245.00 $1051.00 | 7 | |
Androgen receptor inhibitor, could influence hormone signaling pathways affecting Olr180. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
BCR-ABL tyrosine kinase inhibitor, might affect signaling pathways relevant to Olr180. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Dual EGFR and HER2 inhibitor, may disrupt growth factor signaling involving Olr180. | ||||||
Niraparib | 1038915-60-4 | sc-507492 | 10 mg | $150.00 | ||
PARP inhibitor, potentially affects DNA repair pathways linked to Olr180. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
CDK4/6 inhibitor, could impact cell cycle regulation pathways involving Olr180. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $197.00 $520.00 $1093.00 | 4 | |
Multi-kinase inhibitor, might modulate various signaling pathways involving Olr180. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
BCL-2 inhibitor, may influence apoptosis pathways potentially linked to Olr180. | ||||||